Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01631214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01631214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 4, 2012
Completion date
June 29, 2017
Enrollment
4,093 (actual)
Sites
316

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal women with osteoporosis